---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-128613"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2022-12-20T23:59:59+00:00"
generated_at: "2026-06-21T02:14:31.775318+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Regeneron enters into new $750M revolving credit facility, replaces prior facility

## Summary
- New $750M senior unsecured five-year revolving credit facility maturing Dec 19, 2027.
- Interest rate variable: SOFR or alternate base rate plus margin tied to debt rating and leverage ratio.
- Includes $500M accordion to increase commitments or add term loans with lender consent.
- ESG amendment option to adjust pricing based on environmental, social, governance targets.
- No borrowings outstanding at closing; prior $750M facility terminated simultaneously.

## SEC filing metadata
- accession: 0001104659-22-128613
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2022-12-20T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 1.01, 1.02, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000110465922128613/0001104659-22-128613-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000110465922128613/tm2233051d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-128613
- JSON: https://secwatch.observer/filing/0001104659-22-128613.json
- Plain text: https://secwatch.observer/filing/0001104659-22-128613.txt

## Key facts
- Debt Financings
  REGENERON PHARMACEUTICALS, INC. incurred revolving credit of $750 million with JPMorgan Chase Bank, N.A. at variable interest rate based on SOFR or alternate base rate plus applicable marg maturing December 19, 2027.
  - Instrument: revolving credit
  - Principal: $750 million
  - Counterparty: JPMorgan Chase Bank, N.A.
  - Rate: variable interest rate based on SOFR or alternate base rate plus applicable marg
  - Maturity: December 19, 2027
  - Event: incurrence
  source text: The Credit Agreement provides for a $750 million senior unsecured five-year revolving credit facility (with a $25 million sublimit for swingline borrowings and a $50 million sublimit for letters of credit)
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000110465922128613/0001104659-22-128613-index.htm
- Material Agreements
  REGENERON PHARMACEUTICALS, INC. terminated Prior Credit Agreement with JPMorgan Chase Bank, N.A. valued at Prior $750 million revolving credit facility terminated (effective 2022-12-19).
  - Action: termination
  - Agreement: credit facility
  - Counterparty: JPMorgan Chase Bank, N.A.
  - Value: Prior $750 million revolving credit facility terminated
  - Effective: 2022-12-19
  source text: On the Closing Date, in connection with the entry into the Credit Agreement as described in Item 1.01 above, the Company terminated its then-existing credit agreement, dated as of December 14, 2018, as amended prior to the Closing Date (the “ Prior Credit Agreement ”), by and among Regeneron, as a borrower and guarantor; certain subsidiaries of Regeneron party thereto as subsidiary borrowers; the lenders and issuing banks from time to time party thereto; and JPMorgan Chase Bank, N.A., as administrative agent, swingline lender, and an issuing bank.
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000110465922128613/0001104659-22-128613-index.htm
- Material Agreements
  REGENERON PHARMACEUTICALS, INC. entered into Credit Agreement with JPMorgan Chase Bank, N.A. valued at $750 million senior unsecured five-year revolving credit facility (effective 2022-12-19).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: JPMorgan Chase Bank, N.A.
  - Value: $750 million senior unsecured five-year revolving credit facility
  - Effective: 2022-12-19
  source text: On December 19, 2022 (the “ Closing Date ”), Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) entered into a credit agreement (the “ Credit Agreement ”) by and among the Company, as a borrower and guarantor; certain direct subsidiaries of the Company, as the initial subsidiary borrowers; the lenders and issuing banks from time to time party thereto; and JPMorgan Chase Bank, N.A., as administrative agent, swingline lender, and an issuing bank. The Credit Agreement provides for a $750 million senior unsecured five-year revolving credit facility
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000110465922128613/0001104659-22-128613-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.